NIH-funded research U01 cooperative agreement

Monthly risedronate pill to protect bones after sleeve gastrectomy

Official title: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

Funded at Wake Forest University · NIH-11322517 · Data updated 2026-11-12

This will see if a once-monthly risedronate pill helps protect bone health for people who have had sleeve gastrectomy.

More Bariatric Surgery research and trials

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionWake Forest University
NIH-funded
Lab location1 site (Winston-Salem, United States)
Project startMay 20, 2022
Project endApril 30, 2028
Funding year2026
Award (this year)$591,370
NIH project number5U01AR080969-04
Project IDNIH-11322517 on NIH RePORTER

Who could benefit from this research

Could help

Adults who have undergone sleeve gastrectomy and meet medical safety criteria for taking oral risedronate would be ideal candidates.

Less likely to help

People with contraindications to bisphosphonates (for example, certain esophageal disorders, low blood calcium, or severe kidney disease), pregnant or breastfeeding people, or those who cannot take oral medication are unlikely to benefit or be eligible.

What this research studies

If you have had sleeve gastrectomy, you may be invited to join a trial where participants are randomly given either a once-monthly oral risedronate pill or a placebo. Doctors will track bone mineral density, blood markers of bone breakdown, and body composition over time to see how bones and muscle change after surgery. The trial team may also collect blood samples to explore biological links between bone and muscle. Regular clinic visits will be required for tests and medication checks.

Why it matters

Potential benefit: If successful, the treatment could slow bone loss after sleeve gastrectomy and lower long-term fracture risk, and it might also help preserve lean muscle.

How similar studies have gone: Small pilot human studies and animal data suggest risedronate can reduce bone resorption after sleeve gastrectomy and may spare lean mass, but larger definitive trials are still needed.

Where this research is happening

  • Wake Forest University
    Winston-Salem, United States
    Active

Researchers

  • Principal investigator: Beavers, Kristen Marie — Wake Forest University
  • Study coordinator: Beavers, Kristen Marie

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.